Immune monitoring of transplant patients in transient mixed chimerism tolerance trials

Hum Immunol. 2018 May;79(5):334-342. doi: 10.1016/j.humimm.2017.12.011. Epub 2017 Dec 28.

Abstract

This review focuses on mechanistic studies performed in recipients of non-myeloablative bone marrow transplant regimens developed at Massachusetts General Hospital in HLA-identical and HLA-mismatched haploidentical combinations, initially as a platform for treatment of hematologic malignancies with immunotherapy in the form of donor leukocyte infusions, and later in combination with donor kidney transplantation for the induction of allograft tolerance. In patients with permanent mixed chimerism, central deletion may be a major mechanism of long-term tolerance. In patients in whom donor chimerism is only transient, the kidney itself plays a significant role in maintaining long-term tolerance. A high throughput sequencing approach to identifying and tracking a significant portion of the alloreactive T cell receptor repertoire has demonstrated biological significance in transplant patients and has been useful in pointing to clonal deletion as a long-term tolerance mechanism in recipients of HLA-mismatched combined kidney and bone marrow transplants with only transient chimerism.

Keywords: Allograft rejection; Clonal deletion; Donor-specific tolerance; Mixed chimerism; Regulatory T cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Marrow Transplantation*
  • Clonal Deletion / immunology
  • Graft Survival / immunology
  • HLA Antigens / genetics
  • HLA Antigens / immunology
  • Humans
  • Kidney Transplantation*
  • Monitoring, Immunologic*
  • T-Lymphocytes, Regulatory / immunology
  • Transplantation Chimera / immunology*
  • Transplantation Tolerance / immunology*
  • Transplants / immunology
  • Transplants / pathology

Substances

  • HLA Antigens